IL6 and small cell lung carcinoma: Interestingly, patients with low expression levels of IL-6 or TNF-α had longer mOS than those with high expression levels (18.5 vs. 9.5 months, P = 0.026; 18.5 vs. 7.8 months, P = 0.004, respectively) in the ICI-combo cohort but not in the chemotherapy cohort (P = 0.073 and P = 0.222, respectively), suggesting the predictive role of low IL-6 and TNF-α ICI-combo benefits in SCLC.